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ARTICLE
Meta-analysis of genome-wide association for migraine
in six population-based European cohorts
Lannie Ligthart1,2,16, Boukje de Vries3,16, Albert V Smith4, M Arfan Ikram5, Najaf Amin6, Jouke-Jan Hottenga1,
Stephany C Koelewijn3, V Mathijs Kattenberg1, Marleen HM de Moor1, A Cecile JW Janssens6,
Yurii S Aulchenko6, Ben A Oostra6, Eco JC de Geus1, Johannes H Smit7, Frans G Zitman8,
Andre´ G Uitterlinden9, Albert Hofman5, Gonneke Willemsen1, Dale R Nyholt10, Grant W Montgomery11,
Gisela M Terwindt12, Vilmundur Gudnason4,13, Brenda WJH Penninx7,8,14, Monique Breteler5,
Michel D Ferrari12, Lenore J Launer15, Cornelia M van Duijn6,16, Arn MJM van den Maagdenberg3,16
and Dorret I Boomsma1,16 for the Dutch Icelandic migraine genetics consortium (DICE)
Migraine is a common neurological disorder with a genetically complex background. This paper describes a meta-analysis of
genome-wide association (GWA) studies on migraine, performed by the Dutch–Icelandic migraine genetics (DICE) consortium,
which brings together six population-based European migraine cohorts with a total sample size of 10 980 individuals (2446
cases and 8534 controls). A total of 32 SNPs showed marginal evidence for association at a P-valueo105. The best result was
obtained for SNP rs9908234, which had a P-value of 8.00108. This top SNP is located in the nerve growth factor receptor
(NGFR) gene. However, this SNP did not replicate in three cohorts from the Netherlands and Australia. Of the other 31 SNPs,
18 SNPs were tested in two replication cohorts, but none replicated. In addition, we explored previously identified candidate
genes in the meta-analysis data set. This revealed a modest gene-based significant association between migraine and the
metadherin (MTDH) gene, previously identified in the first clinic-based GWA study (GWAS) for migraine (Bonferroni-corrected
gene-based P-value¼0.026). This finding is consistent with the involvement of the glutamate pathway in migraine. Additional
research is necessary to further confirm the involvement of glutamate.
European Journal of Human Genetics (2011) 19, 901–907; doi:10.1038/ejhg.2011.48; published online 30 March 2011
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INTRODUCTION
Migraine is a common neurological disorder that is characterized by
severe attacks of headache accompanied by symptoms such as nausea,
vomiting and photophobia and phonophobia.1 Two main types of
migraine are distinguished based on the presence of an aura that can
precede the headache: migraine with aura (MA) or without aura
(MO). Although MA and MO have been considered distinct disease
entities,2,3 it is now more and more accepted that they represent
different manifestations of the same disease.4–6
Genetic studies in familial hemiplegic migraine (FHM), a rare
monogenic subtype of MA that is considered a suitable model for
common migraine,7 revealed three genes (CACNA1A,8 ATP1A29 and
SCN1A10) that are involved in ion and neurotransmitter transport in
the brain. Despite considerable efforts, linkage and candidate-gene
association studies in common migraine have had limited success,
with only a few consistently replicated linkage findings.11–16 A recent
genome-wide association study (GWAS), using data from migraine
patients who were recruited through headache clinics, found evidence
for a role of the metadherin (MTDH) gene in common migraine.17
The associated SNP in that study affects MTDH gene expression and
thereby indirectly regulates the expression of the glutamate transporter
gene SLC1A2 (also known as EAAT2 or GLT-1), encoding a major
glutamate transporter in the brain. This fits in well with the theory
that increased glutamate release or reduced glutamate uptake increases
the risk of migraine attacks.18–22
Here, we present a GWA meta-analysis for common migraine by
the Dutch Icelandic migraine genetics consortium (DICE). This is the
first population-based GWAS for common migraine, including 2446
migraine cases and 8534 controls from six Dutch and Icelandic
samples. For replication, two population-based samples of Dutch
and one of Australian origin were available. De novo genotyping was
performed in the two Dutch replication cohorts (N¼769 and 337
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cases; 940 and 826 controls, respectively). In addition, an in silico
replication study was performed in the Australian replication cohort
(N¼1851 cases, 4008 controls).
METHODS
Populations: subjects, phenotypes and genotyping
The five Dutch samples that were used for the meta-analysis came from the
Erasmus Rucphen Family (ERF) study,23,24 The Netherlands Study of Depression
and Anxiety (NESDA),25 The Netherlands Twin Registry (‘NTR1’ and ‘NTR2’)26
and the Rotterdam study,27 and included 330, 756, 378, 276 and 349 migraine
cases, respectively. The Icelandic sample came from the AGES-Reykjavik Study
and included 357 migraine cases.28 In addition to the 2446 migraine cases, 8534
non-migraine controls (2862 Icelandic and 5672 Dutch controls) from the
respective cohorts were included (for details, see Table 1). All individuals came
from population-based samples and were unrelated, with the exception of
the ERF participants, who are part of a genetically isolated population in the
Southwest of the Netherlands. Data on migraine symptomatology were collected
by means of questionnaires (ie, AGES, NESDA, NTR1–2, Rotterdam), or a
combination of questionnaires and telephone interview follow-up (ie, ERF).
Three additional independent samples were available for replication; two
Dutch population-based samples (the GEM sample29 and a third sample from
the NTR), and one Australian sample, the Australian Twin Migraine (ATM)
GWA study.30,31 The Dutch GEM sample included 769 migraine cases and 940
non-migraine controls. The NTR replication sample consisted of 337 cases and
826 non-migraine controls, and the Australian sample consisted of 5859
unrelated individuals (1851 migraine cases, 1631 non-migraine controls and
2377 additional unselected controls).
Genotyping was performed using a variety of SNP genotyping platforms.
To ensure sufficient overlap between studies?, genotypes for B2.5 million
HapMap SNPs were imputed using MACH32 or IMPUTE33 software. An
overview of the samples, including details on sample size, genotyping and
imputations, is provided in Table 1. More details on the background of the
studies, phenotyping strategies and genotyping procedures can be found in the
Supplementary data.
GWA and meta-analysis
In each sample, a logistic regression association test was carried out. Next, a
meta-analysis was performed combining the GWA results of the six samples
(total number of individuals: 10 890) using the METAL program (http://
www.sph.umich.edu/csg/abecasis/metal/). As different phenotype definitions
were used in the different samples, the effect sizes may not be directly
comparable between studies. Therefore, a pooled Z-score approach was used.
With the pooled Z-score method, an overall Z-score is calculated based on the
summed Z-scores from the individual studies, weighted by each study’s sample
size. The weights are calculated as the square root of (Nstudy/Ntotal), and the
squared weights sum to one. The direction of effect is indicated by the sign of
the Z-score. To ensure that meta-analysis results were based on SNP data of a
large enough number of individuals, 184 350 SNPs that were available for
o70% of all participants were excluded from the meta-analysis. This left a total
of 2 394 913 autosomal SNPs for analysis. Annotation of meta-analysis results
was performed with WGA viewer version 1.26E (Dongliang Ge and David B
Goldstein; http://people.genome.duke.edu/~dg48/WGAViewer/).34 P-valueso5108
were considered genome-wide significant.35
Replication studies
A replication study was performed with direct genotyping in the GEM and the
NTR replication samples. The top SNP was genotyped with a TaqMan assay in
both GEM and the NTR replication sample. In addition, another 18 SNPs with
a P-valueo1105 were selected based on informativeness given the LD
structure. These SNPs were genotyped in the GEM sample using an in-house
Sequenom iPLEX Mass-ARRAY platform (Sequenom Inc., San Diego, CA,
USA). Logistic regression was performed to test for association between these
SNPs and migraine status. Third, all DICE SNPs with a P-valueo1104 in the
meta-analysis were selected, and for these SNPs, an in silico replication study
was performed in the ATM GWA data set. Finally, the 19 SNPs that were
genotyped in GEM and the NTR replication sample and measured or imputed
in the ATM GWA replication sample were meta-analysed together with the
discovery data sets. A more detailed description of the genotyping procedures
and association analyses can be found in the Supplementary data.
Post hoc analyses
Text mining. Relationships between genes (emerging from the meta-analysis)
and migraine were studied using the Anni text-mining program (Anni version 2.1;
http://www.biosemantics.org/anni).36 For details see the Supplementary data.
Comparison of results with migraine genes and loci from previous studies.
Genome-wide linkage studies and association studies for migraine were
identified with a literature search in PubMed. We examined which SNPs with
a P-valueo1104 coincided with a region containing a published migraine
Table 1 Sample descriptives
Ages ERF NESDA NTR1 NTR2 Rotterdam
Subjects
Total, N 3219 1546 1530 1593 1094 1998
N cases (#, ~) 357 (71, 286) 330 (81, 249) 756 (165, 591) 378 (69, 309) 276 (59, 217) 349 (79, 270)
N controls (#, ~) 2862 (1281,1581) 1216 (615, 601) 774 (322, 452) 1215 (509, 706) 818 (396, 422) 1649 (805, 844)
Mean age (SD) 51.22 (±6.33) 48.4 (±14.6) 42.9 (±12.5) 44.8 (±15.0) 48.6 (±14.4) 55.37 (±4.51)
Genotyping and imputation
Platform Illumina 370CNV Illumina
HumanHap300
HumanHap370
Affymetrix 250K
Nsp array
Perlegen/
Affymetrix 600K
Perlegen/Affymetrix
600K
Illumina
Human660W-Quad
BeadChip
Illumina Infinium II
HumanHap550
version 3.0
Software used
for imputation
MACH 1.0.16 MACH IMPUTE IMPUTE IMPUTE MACH 1.0.15
Reference set HapMap CEU HapMap CEU HapMap CEU HapMap CEU HapMap CEU HapMap CEU
NCBI build 36 36 36 36 36 36
Hapmap release 22 22 22 22 24 22
Number of SNPs analyzed 2 408 991 2 135 034 2 432 125 2 431 993 2 542 087 2 450 030
Software for association
analysis of imputed data
ProbABEL ProbABEL SNPTEST SNPTEST SNPTEST ProbABEL
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linkage peak. In addition, a selection of migraine candidate genes was made and
inspected in our meta-analysis data set by calculating a gene-based P-value for
each of the selected genes using the VEGAS program.37 More details can be
found in the Supplementary methods.
RESULTS
Meta-analysis
GWA analyses were performed in the six population-based samples
and the results were meta-analyzed using a pooled Z-score approach.
As shown in Figure 1, no systematic deviation from the expected
distribution of P-values was observed in the Q–Q plot, which is
reflected by a genomic inflation factor (l) of 1.022. A total of 32 SNPs
had a P-valueo1105 (Table 2). None of these SNPs exceeded the
threshold for genome-wide significance (Figure 2). A total of 10 SNPs
were located within genes; 8 in the metastasis associated in colon
cancer 1 (MACC1) gene (7p21), 1 in the immunoglobulin lambda-like
polypeptide 1 (IGLL1) gene (22q11) and 1 in the nerve growth factor
receptor (NGFR) gene (17q21–q22). The most significant result was
obtained for SNP rs9908234 (P¼8.00108) in the NGFR gene, with
the strongest evidence coming from the AGES and NESDA studies
(Supplementary Table S1). Data for 17 additional SNPs in this
gene were available, but none of these were associated with migraine
(all P-values40.05). These SNPs were not in LD with rs9908234.
Next, we performed text mining with the Anni program. The concept
‘migraine’ was matched against the genes located within or close to
our top SNPs (P-valueo1104). Remarkably, the NGFR gene
surfaced as the best migraine candidate gene.
Replication analysis of the top SNPs
From the 32 top SNPs with P-valueso1105, we selected 19 SNPs
for genotyping in the GEM sample. The selection was made such that
the genotyped SNPs were maximally informative given the LD
between them. The top SNP rs9908234, located in the NGFR gene,
was genotyped in one additional replication sample from the NTR.
The association observed in the discovery samples could not be
replicated for rs9908234 (GEM: OR¼0.86, P¼0.31; NTR replication
sample: OR¼0.89, P¼0.579; see Supplementary Table S2). The find-
ings for the other 18 SNPs were not replicated either. None showed a
P-valueo0.05 in the GEM sample: the smallest P-value observed was
0.10, but this effect was in the opposite direction compared with the
meta-analysis.
Figure 1 Q–Q plot showing the expected and observed distribution of
P-values in the meta-analysis that included the five Dutch samples and the
Icelandic sample. The genomic inflation factor (l) for the meta-analysis was
1.022.
Table 2 Selected SNPs with P-valueso1105 in the meta-analysis
SNP Chr P-value
Base-pair
position Type of SNP Nearest gene
Distance to
gene (kb) A1 A2 Frequency A1
Direction
of effecta
Number of SNPs
in region (Po1105)
rs9908234 17 8.00108 44 932 347 Intronic NGFR 0 A G 0.93  1
rs11636768 15 3.23107 85 496 515 Intergenic AGBL1 164.2 A G 0.15 ++++?+ 1
rs10275320 7 1.56106 20 148 579 Intronic MACC1 0 A G 0.15  8
rs4939879 18 1.82106 45 399 981 Intergenic LIPG 26.7 A G 0.47 ++++++ 1
rs4861775 4 3.28106 180 553 645 Intergenic AGA 1953.1 A C 0.81  1
rs986222 10 3.37106 91 920 867 Intergenic KIF20B 396.2 A G 0.46 ++++++ 16
rs6107848 20 5.90106 6 539 116 Intergenic BMP2 157.6 A G 0.37 +++++ 1
rs140174 22 6.98106 22 252 983 Intronic IGLL1 0 A G 0.75  1
rs1146161 1 9.27106 115 460 299 Intergenic TSPAN2 26.7 A C 0.18 ++++++ 1
rs4742323 9 9.70106 7 276 743 Intergenic KDM4C 111.1 C G 0.61  1
Abbreviations: Chr¼chromosome; A1¼effect allele in meta-analysis; A2¼non-effect allele.
A total of 32 SNPs had a P-valueo1105. In case multiple SNPs were located close together in the same region, the most significant SNP is reported. In the last column, the number of
neighboring SNPs that exceeded the threshold is shown (chromosome 7: 8 SNPs within a 43.7kb region; chromosome 10: 16 SNPs in a 104.3kb region).
aThe direction of effect of the respective SNP is given for each of the six samples in the following order: AGES, ERF, NESDA, NTR1, NTR2, Rotterdam. A question mark indicates that a SNP
was not tested in a particular sample (because it was removed during quality control). Positions are based on NCBI Build 36. The frequency of A1 was calculated as a weighted average across
all samples.
Figure 2 Manhattan plot showing the P-values by chromosome for the
meta-analysis.
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An in silico replication study was performed in the ATM GWA
sample. This analysis included all SNPs with P-valueso1104 in the
DICE meta-analysis. In the ATM GWA sample, there were data for 327
out of 340 SNPs with P-valueso1104. None of these SNPs had
a P-valueo0.01 in the ATM GWA data set. A total of 11 SNPs
had P-values between 0.01 and 0.05, but for only 3 SNPs, the effect was
in the same direction as in the DICE cohorts (rs6919479, P¼0.045;
rs9363693, P¼0.045; and rs9294736, P¼0.037; all on chromosome 6).
These results were not significant after correction for multiple testing.
Finally, a new meta-analysis was carried out in the DICE discovery
samples, the GEM sample and the ATM GWA sample, for the 19 SNPs
genotyped in GEM. For rs9908234, the meta-analysis also included the
NTR replication cohort. The P-values for these SNPs did not decrease
compared with the first meta-analysis (Supplementary Table S2).
Comparison of meta-analysis results with previous genetic findings
in migraine
The large sample size of the present study provided a unique
opportunity to further investigate previous findings from linkage
and candidate gene studies on a larger scale, and to try and replicate
the findings recently reported in a large clinic-based GWAS for
migraine.17
First, we investigated whether there were any SNPs with
P-valueso104 that were located in previously identified migraine
linkage regions (Supplementary Table S3). Five SNPs were located on
chromosome 10q22–q23, a locus that has been reported for migraine
several times.11,15,16 However, none were located in or near a gene that
could easily be linked to migraine pathophysiology. Interestingly, one
SNP (rs1972860, P¼6.02105) was located in the glutamate recep-
tor, ionotropic, delta 2 (GRID2) gene on chromosome 4q22, a region
reported in several different migraine linkage studies.11–14
In addition, we performed a gene-based association test for selected
candidate genes for migraine (Table 3). Seven candidate genes were
selected based on the results of previous candidate gene association
studies for common migraine. Furthermore, a recently published
GWAS of clinic-based migraine identified an SNP (rs1835740) that
was located between two interesting candidate genes: the MTHD gene
and the plasma glutamate carboxypeptidase (PGCP) gene.17 An eQTL
analysis revealed that rs1835740 most likely affects migraine through
cis-regulation of MTHD, which in turn downregulates SLC1A2,
a gene that encodes an important glutamate transporter in the
brain. Therefore, we selected MTHD, PGCP and SLC1A2 as candidate
genes, and also inspected SNP rs1835740 and two nearby correlated
SNPs (rs982502 and rs2436046). Finally, the three FHM genes
(CACNA1A, ATP1A2 and SCN1A) were included in the analysis.
Gene-based tests were performed for each of the selected candidate
genes, using the meta-analysis results of all SNPs tested in the
respective genes (Table 3). A gene-based test result was considered
significant at an alpha level of 0.05, with Bonferroni correction for 13
tests, which corresponds to a gene-based P-value of 0.05/13¼0.0038.
None of the genes identified through candidate gene association
studies was significantly associated with migraine in the meta-analysis.
Although there were nominally significant SNPs in the LTA, ESR1 and
INSR genes, results were not significant after correction for the
number of SNPs tested within the respective genes. The PGCP and
SLC1A2 genes also had several nominally significant SNPs, but again
were not significant in the gene-based test. However, in the MTHD
gene, 19 of the 28 tested SNPs had a P-valueo0.01 in the meta-
analysis (Supplementary Table S4). The gene-based P-value for MTDH
was 0.002, which remained significant after Bonferroni correction.
The SNP that showed association in the clinic-based GWA study Ta
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(rs1835740)17 did not show significant association with migraine in
the meta-analysis (P¼0.64). Two nearby SNPs (rs982502 and
rs2436046) reported in the same GWAS were also not associated
with migraine in the present study.
Finally, we tested the three FHM genes, and found several nominally
significant SNPs within CACNA1A and ATP1A2. The gene-based test
for CACNA1A (best SNP rs3764615, P¼0.004) was not significant
(P¼0.30). The gene-based P-value for ATP1A2 (best SNP rs2854248,
P¼3.62104) was 0.006.
DISCUSSION
This study describes the first meta-analysis of GWAS for population-
based migraine, and contains a total of 2446 migraine cases and 8534
controls. The best P-value was obtained for SNP rs9908234, which is
located in the NGFR gene. A replication study was performed in two
Dutch replication cohorts that were available for wet replication; the
GEM cohort (769 cases, 940 controls) and the NTR replication cohort
(337 cases, 826 controls). In addition, the ATM GWA cohort (1851
cases, 1631 controls) was available for in silico replication. Although
the NGFR gene is an interesting candidate gene for migraine, the
association of NGFR with migraine could not be replicated in these
cohorts. A total of 18 additional top SNPs (P-valueo105) from the
meta-analysis were tested in the GEM cohort and the ATM GWA
cohort, but none could be replicated successfully.
There are several possible explanations for the lack of replication.
First, several different genotyping platforms were used, which made
imputation necessary to ensure sufficient overlap between the studies.
Also, two different programs (MACH and IMPUTE) were used for
imputation. However, given that MACH and IMPUTE use very
similar imputation algorithms, and have been reported to be very
similar in imputation accuracy,38 we do not expect this to have a
major effect on our results. Second, there were some differences
between the samples in the precision of the migraine diagnoses, and
in most samples, a clinical migraine diagnosis was not available. This
is often the case in population-based studies because, for reasons of
efficiency, diagnoses are commonly made with (short) headache
questionnaires. Unlike in clinic-based studies, they are not usually
further evaluated with more extensive questionnaires or interviews by
specialized physicians. Less accuracy of diagnosis may result in
reduced power to detect association. The phenotypic differences also
extend to the control groups, as all non-migraine individuals were
included as controls. These differences between studies mean that
effect sizes may not be directly comparable. To address this, a pooled
Z-score meta-analysis was performed. This type of analysis does not
require a direct comparison of effect sizes.39 Third, population-based
cohorts also include many patients who have less severe migraine and
a lower attack frequency. This means that they might be a genetically
more heterogeneous group than patients from clinic-based cohorts. In
addition, they are likely to have a lower genetic risk of migraine than
the more severely affected patients in clinic-based cohorts. As a
consequence, population-based studies may require a larger number
of patients for sufficient power. Given that this study replicates
previous findings, but does not produce genome-wide significant
results, insufficient power (possibly because of the reasons above)
seems the most likely explanation for the lack of replication of our top
results. A lack of power makes it difficult to distinguish between true
associations and false-positive findings in the original meta-analysis.
Therefore, when the discovery samples have insufficient power, SNPs
selected for replication based on small P-values may not replicate
(even in sufficiently large replication samples) because they are false
positives. Finally, it should be mentioned that the NESDA sample
differed from the other samples because the majority of NESDA
participants were selected for major depression. Because of the
comorbidity of migraine and major depression, there is a higher
prevalence of migraine in this sample than in the other samples.
However, given that the percentage of MDD was similar in the
migraine cases and the controls (94.3 vs 86.6%), any associations
detected in this sample will be related to migraine and not to MDD.
In the present study, we also investigated SNP rs1835740 that was
found to be significantly associated with MA in the first GWA study of
clinic-based populations.17 This SNP is located on 8q21 between the
MTDH and PGCP genes. The SNP itself was not associated with
migraine in our study, but our gene-based analyses provided modest
support for an association of MTDH with migraine.
In summary, although this study does not provide genome-wide
significant association of an SNP with migraine, it provides suggestive
evidence for an association with the MTDH gene, which is involved in
the glutamate pathway, previously hypothesized to have a role in
migraine based on findings in FHM.40 Clearly, even though a large
number of patients and controls were included, the present study
suffered from a lack of power. In addition to simply increasing the
sample size, additional strategies aimed at minimizing phenotypic and
genetic heterogeneity may be necessary. Strategies to achieve this can
include the identification of reliable biomarkers or stratification of
samples based on phenotypic similarity (eg, by looking at trait
components,11 specific symptoms16,41 and/or comorbid pathology).
In addition, in future studies it may be worth focusing specifically on
the glutamate pathway to assess whether genetic variants affecting
glutamate levels are systematically associated with migraine.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
The Age, Gene/Environment Susceptibility Reykjavik Study is funded by NIH
contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd
(the Icelandic Heart Association) and the Althingi (the Icelandic Parliament).
The Erasmus Rucphen Family was supported by grants from The Netherlands
Organization for Scientific Research (NWO), Erasmus MC and the Netherlands
Genomics Initiative (NGI)-sponsored Center of Medical Systems Biology
(CMSB). The genotyping for the ERF study was supported by EUROSPAN
(European Special Populations Research Network) through the European
Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study
was further supported by grants from the Netherlands Organisation for
Scientific Research (NWO) (903-52-291, M.D.F., Vici 918.56.602, M.D.F,
907-00-217 G.M.T.), Erasmus MC, the Centre for Medical Systems Biology
(CMSB1 and CMSB2), and the Netherlands Genomics Initiative (NGI). We are
grateful to all patients and their relatives, general practitioners and neurologists
for their contributions and to P Veraart for her help in genealogy, Jeannette
Vergeer for the supervision of the laboratory work and P Snijders for his help
in data collection. For NESDA and NTR, funding was obtained from
the Netherlands Organization for Scientific Research (NWO: MagW/ZonMW):
Genetic basis of anxiety and depression (904-61-090); Genetics of individual
differences in smoking initiation and persistence (NWO 985-10-002); Resolving
cause and effect in the association between exercise and well-being (904-61-
193); Twin family database for behavior genomics studies (480-04-004);
Twin research focusing on behavior (400-05-717); Genetic determinants of risk
behavior in relation to alcohol use and alcohol use disorder (Addiction-
31160008); Genotype/phenotype database for behavior genetic and genetic
epidemiological studies (40-0056-98-9032); Spinozapremie (SPI 56-464-14192);
CMSB: Center for Medical Systems Biology (NWO Genomics); NBIC/
BioAssist/RK/2008.024); BBMRI –NL: Biobanking and Biomolecular Resources
Research Infrastructure (184.021.007); the VU University: Institute for Health
and Care Research (EMGO+ ) and Neuroscience Campus Amsterdam (NCA);
GWA meta-analysis for migraine
L Ligthart et al
905
European Journal of Human Genetics
the European Science Foundation (ESF): Genomewide analyses of European
twin and population cohorts (EU/QLRT-2001-01254); European Community’s
Seventh Framework Program (FP7/2007-2013): ENGAGE (HEALTH-F4-2007-
201413); the European Science Council (ERC) Genetics of Mental Illness
(230374); Rutgers University Cell and DNA Repository cooperative agreement
(NIMH U24 MH068457-06); Collaborative study of the genetics of DZ
twinning (NIH R01D0042157-01A); the Genetic Association Information
Network, a public–private partnership between the NIH and Pfizer Inc.,
Affymetrix Inc. and Abbott Laboratories. The infrastructure for the NESDA
study (http://www.nesda.nl) is funded through the Geestkracht program of the
Netherlands Organization for Health Research and Development (ZonMw,
Grant number 10-000-1002) and is supported by participating universities and
mental health care organizations (VU University Medical Center, GGZ inGeest,
Arkin, Leiden University Medical Center, GGZ Rivierduinen, University
Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific
Institute for Quality of Health Care (IQ Healthcare), Netherlands Institute
for Health Services Research (NIVEL) and Netherlands Institute of Mental
Health and Addiction (Trimbos)). SNP genotyping was funded by the Genetic
Association Information Network (GAIN) of the Foundation for the US
National Institutes of Health (NTR1/NESDA) and the Spinozapremie
(NWO/SPI 56-464-14192; NTR2). Statistical analyses were partly carried out on
the Genetic Cluster Computer (NWO 480-05-003). The Rotterdam Study
(I, I, and II) are funded by Erasmus Medical Center and Erasmus University,
Rotterdam, Netherlands Organization for the Health Research and Develop-
ment (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the
Ministry of Education, Culture and Science, the Ministry for Health,
Welfare and Sports, the European Commission (DG XII), the Netherlands
Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy
Aging (NCHA) and the Municipality of Rotterdam. The generation and
management of GWAS genotype data for the Rotterdam Study is supported
by the Netherlands Organization of Scientific Research NWO Investments
(nr. 175.010.2005.011, 911-03-012). The Rotterdam Study is funded by Erasmus
Medical Center and Erasmus University, Rotterdam, Netherlands Organization
for the Health Research and Development (ZonMw), the Research Institute for
Diseases in the Elderly (RIDE and RIDE2), the Ministry of Education, Culture
and Science, the Ministry for Health, Welfare and Sports, the European
Commission (DG XII), the Municipality of Rotterdam and the Netherlands
Genomics Initiative (NGI)/Netherlands Organization for Scientific Research
(NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael
Moorhouse, Marijn Verkerk and Sander Bervoets for their help in creating the
GWAS database. We are grateful to the study participants, the staff from the
Rotterdam Study and the participating general practioners and pharmacists.
For the Australian cohort, we thank the Australian National Health and Medical
Research Council (NHMRC; Grants 241944, 339462, 389927, 389875, 389891,
389892, 389938, 443036, 442915, 442981, 496739, 552485 and 552498) and the
Australian Research Council (A7960034, A79906588, A79801419, DP0212016
and DP0343921) for funding. GWM and DRN are supported by the NHMRC
Fellowship and the Australian Research Council Future Fellowship Schemes.
We thank N Martin, P Visscher, D Duffy, A Henders, B Usher, E Souzeau,
A Kuot, A McMellon, MJ Wright, MJ Campbell, A Caracella, L Bowdler,
S Smith, S Gordon, B Haddon, D Smyth, H Beeby, O Zheng and B Chapman
for their input into project management, databases, phenotype collection,
and sample collection, processing and genotyping.
1 Headache classification subcommittee of the International Headache Society: The
International Classification of Headache Disorders, 2nd edn. Cephalalgia, 2004, Vol 24
(Suppl 1), pp 9–160.
2 Russell MB, Rasmussen BK, Fenger K, Olesen J: Migraine without aura and migraine
with aura are distinct clinical entities: a study of four hundred and eighty-four male and
female migraineurs from the general population. Cephalalgia 1996; 16: 239–245.
3 Russell MB, Ulrich V, Gervil M, Olesen J: Migraine without aura and migraine with aura
are distinct disorders. A population-based twin survey. Headache 2002; 42: 332–336.
4 Kallela M, Wessman M, Havanka H, Palotie A, Farkkila M: Familial migraine with and
without aura: clinical characteristics and co-occurrence. Eur J Neurol 2001; 8: 441–449.
5 Ligthart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR: Migraine with aura and
migraine without aura are not distinct entities: further evidence from a large Dutch
population study. Twin Res Hum Genet 2006; 9: 54–63.
6 Nyholt DR, Gillespie NG, Heath AC, Merikangas KR, Duffy DL, Martin NG: Latent class
and genetic analysis does not support migraine with aura and migraine without aura as
separate entities. Genet Epidemiol 2004; 26: 231–244.
7 Ferrari MD, Van den Maagdenberg AM, Frants RR, Goadsby PJ: Migraine as a cerebral
ionopathy with impaired central sensory processing; in Waxman SG (ed): Molecular
Neurology. Amsterdam: Elsevier, 2007, pp 439–461.
8 Ophoff RA, Terwindt GM, Vergouwe MN et al: Familial hemiplegic migraine and
episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.
Cell 1996; 87: 543–552.
9 De Fusco M, Marconi R, Silvestri L et al: Haploinsufficiency of ATP1A2 encoding the
Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat
Genet 2003; 33: 192–196.
10 Dichgans M, Freilinger T, Eckstein G et al: Mutation in the neuronal voltage-gated
sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366:
371–377.
11 Anttila V, Kallela M, Oswell G et al: Trait components provide tools to dissect the
genetic susceptibility of migraine. Am J Hum Genet 2006; 79: 85–99.
12 Oedegaard KJ, Greenwood TA, Lunde A, Fasmer OB, Akiskal HS, Kelsoe JR: A genome-
wide linkage study of bipolar disorder and co-morbid migraine: replication of migraine
linkage on chromosome 4q24, and suggestion of an overlapping susceptibility region
for both disorders on chromosome 20p11. J Affect Disord 2010; 122: 14–26.
13 Wessman M, Kallela M, Kaunisto MA et al: A susceptibility locus for migraine with
aura, on chromosome 4q24. Am J Hum Genet 2002; 70: 652–662.
14 Bjornsson A, Gudmundsson G, Gudfinnsson E et al: Localization of a gene for migraine
without aura to chromosome 4q21. Am J Hum Genet 2003; 73: 986–993.
15 Anttila V, Nyholt DR, Kallela M et al: Consistently replicating locus linked to migraine
on 10q22-q23. Am J Hum Genet 2008; 82: 1051–1063.
16 Nyholt DR, Morley KI, Ferreira MA et al: Genomewide significant linkage to migrainous
headache on chromosome 5q21. Am J Hum Genet 2005; 77: 500–512.
17 Anttila V, Stefansson H, Kallela M et al: Genome-wide association study of
migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;
42: 869–873.
18 Andreou AP, Goadsby PJ: Therapeutic potential of novel glutamate receptor antagonists
in migraine. Expert Opin Investig Drugs 2009; 18: 789–803.
19 Ferrari MD: Migraine. Lancet 1998; 351: 1043–1051.
20 Goadsby PJ, Classey JD: Glutamatergic transmission in the trigeminal nucleus
assessed with local blood flow. Brain Res 2000; 875: 119–124.
21 van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD: Migraine: gene mutations
and functional consequences. Curr Opin Neurol 2007; 20: 299–305.
22 Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M: Neuroexcitatory amino acid
levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993;
13: 89–93.
23 Sleegers K, de Koning I, Aulchenko YS et al: Cerebrovascular risk factors do not
contribute to genetic variance of cognitive function: the ERF study. Neurobiol Aging
2007; 28: 735–741.
24 Stam AH, de Vries B, Janssens AC et al: Shared genetic factors in migraine and
depression. Evidence from a genetic isolate. Neurology 2010; 74: 288–294.
25 Penninx BW, Beekman AT, Smit JH et al: The Netherlands Study of Depression and
Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res
2008; 17: 121–140.
26 Boomsma DI, de Geus EJ, Vink JM et al: Netherlands Twin Register: from twins to twin
families. Twin Res Hum Genet 2006; 9: 849–857.
27 Hofman A, Breteler MM, van Duijn CM et al: The Rotterdam Study: objectives and
design update. Eur J Epidemiol 2007; 22: 819–829.
28 Scher AI, Gudmundsson LS, Sigurdsson S et al: Migraine headache in middle age and
late-life brain infarcts. JAMA 2009; 301: 2563–2570.
29 Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in
a population-based cohort: the GEM study. Neurology 1999; 53: 537–542.
30 Medland SE, Zayats T, Glaser B et al: A variant in LIN28B is associated with 2D:4D
finger-length ratio, a putative retrospective biomarker of prenatal testosterone expo-
sure. Am J Hum Genet 2010; 86: 519–525.
31 Nyholt DR, LaForge KS, Kallela M et al: A high-density association screen of 155 ion
transport genes for involvement with common migraine. Hum Mol Genet 2008; 17:
3318–3331.
32 Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR: MaCH: Using sequence and genotype
data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2006; 34:
816–834.
33 Marchini J, Howie B, Myers S, McVean G, Donnelly P: A new multipoint method for
genome-wide association studies by imputation of genotypes. Nature genetics 2007;
39: 906–913.
34 Ge D, Zhang D, Need AC et al: WGAViewer: Software for Genomic Annotation of Whole
Genome Association Studies. Genome Res 2008; 18: 640–643.
35 Dudbridge F, Gusnanto A: Estimation of significance thresholds for genomewide
association scans. Genet Epidemiol 2008; 32: 227–234.
36 van Haagen HH, t Hoen PA, Botelho Bovo A et al: Novel protein-protein interactions
inferred from literature context. PLoS One 2009; 4: e7894.
37 Liu JZ, McRae AF, Nyholt DR et al: A versatile gene-based test for genome-wide
association studies. Am J Hum Genet 2010; 87: 139–145.
38 Nothnagel M, Ellinghaus D, Schreiber S, Krawczak M, Franke A: A comprehensive
evaluation of SNP genotype imputation. Hum Genet 2009; 125: 163–171.
39 De Bakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, Voight BF: Practical
aspects of imputation-driven meta-analysis of genome-wide association studies.
Hum Mol Genet 2008; 17: R122–R128.
GWA meta-analysis for migraine
L Ligthart et al
906
European Journal of Human Genetics
40 De Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM: Molecular genetics of
migraine. Hum Genet 2009; 126: 115–132.
41 Ligthart L, Nyholt DR, Hottenga JJ, Distel MA, Willemsen G, Boomsma DI: A genome-
wide linkage scan provides evidence for both new and previously reported loci
influencing common migraine. Am J Med Genet B Neuropsychiatr Genet 2008;
147B: 1186–1195.
42 Schurks M, Rist PM, Kurth T: MTHFR 677C4T and ACE D/I polymorphisms in
migraine: a systematic review and meta-analysis. Headache 2009; 50: 588–599.
43 Schurks M, Zee RY, Buring JE, Kurth T: Interrelationships among the MTHFR 677C4T
polymorphism, migraine, and cardiovascular disease. Neurology 2008; 71:
505–513.
44 Schurks M, Zee RY, Buring JE, Kurth T: MTHFR 677C-T and ACE D/I polymorphisms
and migraine attack frequency in women. Cephalalgia 2010; 30: 447–456.
45 Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L: Association of the C677T
polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia 2009;
29: 818–825.
46 Scher AI, Terwindt GM, Verschuren WM et al: Migraine and MTHFR C677T genotype in
a population-based sample. Ann Neurol 2006; 59: 372–375.
47 Oterino A, Valle N, Pascual J et al: Thymidylate synthase promoter tandem repeat and
MTHFD1 R653Q polymorphisms modulate the risk for migraine conferred by the
MTHFR T677 allele. Brain Res 2005; 139: 163–168.
48 Lee KA, Jang SY, Sohn KM et al: Association between a polymorphism in the
lymphotoxin-a promoter region and migraine. Headache 2007; 47: 1056–1062.
49 Asuni C, Stochino ME, Cherchi A et al: Migraine and tumour necrosis factor
gene polymorphism. An association study in a Sardinian sample. J Neurol 2009;
256: 194–197.
50 Rainero I, Grimaldi LM, Salani G et al: Association between the tumor necrosis
factor-alpha -308 G/A gene polymorphism and migraine. Neurology 2004; 62:
141–143.
51 Oterino A, Toriello M, Cayon A et al: Multilocus analyses reveal involvement of the
ESR1, ESR2, and FSHR genes in migraine. Headache 2008; 48: 1438–1450.
52 Oterino A, Pascual J, Ruiz de Alegria C et al: Association of migraine and ESR1 G325C
polymorphism. Neuroreport 2006; 17: 61–64.
53 Kaunisto MA, Kallela M, Hamalainen E et al: Testing of variants of the MTHFR and
ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine
with aura. Cephalalgia 2006; 26: 1462–1472.
54 Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR: Evidence for allelic
association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical
migraine. Neurogenetics 2000; 3: 35–40.
55 Fernandez F, Colson N, Quinlan S, MacMillan J, Lea RA, Griffiths LR: Association
between migraine and a functional polymorphism at the dopamine beta-hydroxylase
locus. Neurogenetics 2009; 10: 199–208.
56 Fernandez F, Lea RA, Colson NJ, Bellis C, Quinlan S, Griffiths LR: Association between
a 19bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and
migraine with aura. J Neurol Sci 2006; 251: 118–123.
57 Paterna S, Di Pasquale P, D’Angelo A et al: Angiotensin-converting enzyme gene
deletion polymorphism determines an increase in frequency of migraine attacks in
patients suffering from migraine without aura. Eur Neurol 2000; 43: 133–136.
58 McCarthy LC, Hosford DA, Riley JH et al: Single-nucleotide polymorphism alleles in
the insulin receptor gene are associated with typical migraine. Genomics 2001; 78:
135–149.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works
3.0 Unported Licence. To view a copy of this licence, visit http://
creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
GWA meta-analysis for migraine
L Ligthart et al
907
European Journal of Human Genetics
